ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,258.61
0.00%
Dow Jones
44,860.31
0.28%
Gold vs US Dollar
2,646.595
0.54%
Brent Oil
72.665
0.30%
Bitcoin
93,425.74
1.58%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Roquefort Therapeutics Plc (ROQ)

  7. Roquefort Therapeutics Plc (ROQ) News

Roquefort Therapeutics (ROQ)

Roquefort Therapeutics Plc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:ROQ
DateTimeSourceHeadlineSymbolCompany
07/11/202407:00RNS Regulatory NewsRoquefort Therapeutics PLC Conversion of Convertible Loan NotesLSE:ROQRoquefort Therapeutics Plc
06/11/202407:00RNS Non-RegulatoryRoquefort Therapeutics PLC STAT-6 siRNA PresentationLSE:ROQRoquefort Therapeutics Plc
27/09/202412:56Alliance NewsAlliance NewsEARNINGS: Kendrick Resources loss narrows; Emmerson CFO to departLSE:ROQRoquefort Therapeutics Plc
27/09/202412:56Alliance NewsAlliance NewsEARNINGS: Kendrick Resources loss narrows; Emmerson CFO to departLSE:ROQRoquefort Therapeutics Plc
27/09/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Interim Results to 30 June 2024LSE:ROQRoquefort Therapeutics Plc
23/09/202416:51Alliance NewsAlliance NewsRoquefort Therapeutics says MK cell therapy patent approved in JapanLSE:ROQRoquefort Therapeutics Plc
23/09/202416:51Alliance NewsAlliance NewsRoquefort Therapeutics says MK cell therapy patent approved in JapanLSE:ROQRoquefort Therapeutics Plc
23/09/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Grant of Japan MK Cell PatentLSE:ROQRoquefort Therapeutics Plc
19/09/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC STAT-6 siRNA Demonstrates Efficacy in ImmunologyLSE:ROQRoquefort Therapeutics Plc
02/09/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Grant of MK Cell Patent & Licencing UpdateLSE:ROQRoquefort Therapeutics Plc
27/06/202411:46RNS Regulatory NewsRoquefort Therapeutics PLC Results of AGMLSE:ROQRoquefort Therapeutics Plc
20/06/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Appointment of BrokerLSE:ROQRoquefort Therapeutics Plc
04/06/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Notice of Annual General MeetingLSE:ROQRoquefort Therapeutics Plc
23/05/202420:25Alliance NewsAlliance NewsTRADING UPDATES: Windward wins deal; Kodal progresses at BougouniLSE:ROQRoquefort Therapeutics Plc
23/05/202420:25Alliance NewsAlliance NewsTRADING UPDATES: Windward wins deal; Kodal progresses at BougouniLSE:ROQRoquefort Therapeutics Plc
23/05/202406:05RNS Regulatory NewsRoquefort Therapeutics PLC Issue of Convertible Loan Notes & Board ChangesLSE:ROQRoquefort Therapeutics Plc
23/05/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Midkine Antibody Licencing DealLSE:ROQRoquefort Therapeutics Plc
26/04/202419:59Alliance NewsAlliance NewsEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyLSE:ROQRoquefort Therapeutics Plc
26/04/202419:59Alliance NewsAlliance NewsEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyLSE:ROQRoquefort Therapeutics Plc
26/04/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Annual Report & Financial Statements - 31 Dec 2023LSE:ROQRoquefort Therapeutics Plc
05/04/202411:32Alliance NewsAlliance NewsIN BRIEF: Roquefort cancels fundraise after "unusual" stock movementsLSE:ROQRoquefort Therapeutics Plc
05/04/202411:32Alliance NewsAlliance NewsIN BRIEF: Roquefort cancels fundraise after "unusual" stock movementsLSE:ROQRoquefort Therapeutics Plc
05/04/202406:00RNS Regulatory NewsRoquefort Therapeutics PLC Response to Share Price MovementLSE:ROQRoquefort Therapeutics Plc
11/03/202411:12Alliance NewsAlliance NewsRoquefort celebrates "significant milestones" in cancer researchLSE:ROQRoquefort Therapeutics Plc
11/03/202411:12Alliance NewsAlliance NewsRoquefort celebrates "significant milestones" in cancer researchLSE:ROQRoquefort Therapeutics Plc
11/03/202407:00RNS Regulatory NewsRoquefort Therapeutics PLC Positive Results: Midkine mRNA and STAT-6 siRNALSE:ROQRoquefort Therapeutics Plc
06/02/202416:50Alliance NewsAlliance NewsIN BRIEF: Roquefort hails further MK studies, licence talks continueLSE:ROQRoquefort Therapeutics Plc
06/02/202416:50Alliance NewsAlliance NewsIN BRIEF: Roquefort hails further MK studies, licence talks continueLSE:ROQRoquefort Therapeutics Plc
06/02/202407:00RNS Regulatory NewsRoquefort Therapeutics PLC Operations UpdateLSE:ROQRoquefort Therapeutics Plc
24/11/202307:00UK RegulatoryRoquefort Therapeutics PLC Change of AuditorLSE:ROQRoquefort Therapeutics Plc
 Showing the most relevant articles for your search:LSE:ROQ

Your Recent History

LSE
EZJ
Easyjet
LSE
SCLP
Scancell
LSE
VAST
Vast Resources
LSE
BARC
Barclays
LSE
GDR
Genedrive
LSE
EDEN
Eden Research
LSE
AAZ
Anglo Asian Mining
LSE
ZED
Zenova
LSE
GWMO
Great Western Mining
LSE
ENT
Entain
LSE
IPO
Ip
LSE
AML
Aston Martin Lagonda Glo...
LSE
UPS
LSE
BOO
Boohoo
LSE
ONT
Oxford Nanopore Technolo...
LSE
ALBA
Alba Mineral Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Gold Trader

    1 year 35%, 2 years 45% and *3 years 60%

    *Across 3 years £3655.44 only £1462.17